A 284-patient postapproval study presented at the American Thoracic Society's annual meeting showed the use of Boston Scientific's Alair bronchial thermoplasty treatment device was associated with long-term improvement in asthma control. Treatment demonstrated a lower rate of severe exacerbations, from 77.8% to 50.6% at one year and to 45.4% at two years, as well as reductions in the rates of hospitalization and emergency department utilization.
Trial shows positive results for Boston Scientific's Alair asthma device
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.